AI assistant
Sending…
Cartesian Therapeutics, Inc. — Director's Dealing 2023
Jan 4, 2023
33483_dirs_2023-01-04_f2bad2fb-2e23-4cb6-96b1-9823825c7c53.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2023-01-02
Reporting Person: SPRINGER TIMOTHY A (Director, 10% Owner)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-01-02 | Stock Option (Right to Buy) | $1.13 | A | 75000 | Acquired | 2033-01-01 | Common Stock (75000.0) | Direct |
Footnotes
F1: The shares of Common Stock underlying this award will vest in full on January 2, 2024.
More from Cartesian Therapeutics, Inc.
Capital/Financing Update
2026
May 26
Share Issue/Capital Change
2026
Apr 30
Interim / Quarterly Report
2026
Apr 30
Earnings Release
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 28
Board/Management Information
2026
Mar 30
Major Shareholding Notification
2026
Feb 5
Investor Presentation
2026
Jan 9
Director's Dealing
2026
Jan 8
Director's Dealing
2026
Jan 8